adalimumab

Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Will new biosimilars hurt blockbuster autoimmune drug?
Will new biosimilars hurt blockbuster autoimmune drug?New biosimilars may harm the sales of this autoimmune blockbuster.
Pain control benefits HS patientsAdalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Adalimumab promising in treating JIA-associated uveitis, study findsResults from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
TNF alfpha inhibitor safety, efficacy data growsLong-term follow-up studies and drug registries continue to deliver reassuring data regarding the safety and efficacy of TNF inhibitors, an expert says.
Express Scripts’ 2016 Drug Trend Report: 7 things to knowReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.